Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dazucorilant in Amyotrophic Lateral Sclerosis
NCT05407324Phase 2Active, not recruiting
- Sponsor
- Corcept Therapeutics
- Start
- Nov 2022
- Primary completion
- Oct 2026
- Modality
- Orthosteric Ligands
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of dazucorilant in amyotrophic lateral sclerosis (ALS) (4 arms), sponsored by Corcept Therapeutics. Primary endpoints: ALS Functional Rating Scale-Revised total score at 24 weeks and Adverse Events at 24 weeks. Started Nov 2022; status: active, not recruiting.
02
Drugs
dazucorilant
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05407324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05407324.